Current Rheumatology Reports

, Volume 5, Issue 4, pp 270–277

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

  • Ted R. Mikuls
  • Arthur L. Weaver


Tumor necrosis factor-alpha (TNFα) plays a central role in rheumatoid arthritis (RA) pathogenesis. There are cur-rently three available anti-TNFα agents for the treatment of RA—adalimumab, etanercept, and infliximab. These tar-geted therapies have select advantages over traditional disease-modifying antirheumatic drugs (DMARDs), agents that have long been the mainstay of RA treatment. Compared with conventional DMARDs, TNFα inhibitors display a rapid onset of action and have shown a significant effect in retarding the radiographic joint destruction that often char-acterizes RA disease progression. Although anti-TNFα drugs represent an important advance in RA treatment, postmarketing reports of serious infections, as well as other adverse events, highlight the need for continued postmarketing vigilance with the use of these agents. This review evaluates the unique attributes of the available TNFα inhibitors, focusing specifically on recent reports providing important insight into the understanding of drug-related efficacy and toxicity.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Shingu M, Nagai Y, Isayama T, et al.: The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase pro-duction by human chondrocytes and TIMP production by synovial cells and enothelial cells. Clin Exp Immunol 1993, 94:145–149.PubMedCrossRefGoogle Scholar
  2. 2.
    Moser R, Schleiffenbaum B, Groscurth P, Fehr J: Interleukin-1 and tumor necrosis factor stimulate human vascular endot-helial cells to promote transendothelial neutrophil passage. J Clin Invest 1989, 83:444–455.PubMedCrossRefGoogle Scholar
  3. 3.
    US Food and Drug Administration: Etanercept packaging information. etanimm011502LB.pdf. Accessed March 20, 2003.Google Scholar
  4. 4.
    US Food and Drug Administration: Adalimumab packaging information. adalabb123102LB.pdf. Accessed March 20, 2003.Google Scholar
  5. 5.
    Centecor Incorporated: Infliximab packaging information. Accessed March 20, 2003.Google Scholar
  6. 6.
    Scallon B, Moore M, Trinh H, et al.: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmem-brane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251–259.PubMedCrossRefGoogle Scholar
  7. 7.
    Felson D, Anderson J, Boers M, et al.: The American College of Rheumatology preliminary core set of disease activity mea-sures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993, 36:729–740.PubMedCrossRefGoogle Scholar
  8. 8.
    van de Putte L, Atkins C, Malaise M, et al.: Efficacy and safety of adalimumab (D2E7), the first fully human anti-TNF mon-oclonal antibody, in patients with rheumatoid arthritis who failed previous DMARD therapy: 6-month results from a phase III study [abstract]. Ann Rheum Dis 2002, 61(suppl):S168.CrossRefGoogle Scholar
  9. 9.
    van der Heijde D: Plain x-rays in rheumatoid arthritis: over-view of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol 1996, 10:435–453.PubMedCrossRefGoogle Scholar
  10. 10.
    Rau R, Herborn G, Sander O, et al.: Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis [abstract]. Arthri-tis Rheum 1999, 42(suppl):S400.Google Scholar
  11. 11.
    Weinblatt M, Keystone E, Furst D, et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal anti-body, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35–45. Phase III study of adalimumab for use in combination with MTX.PubMedCrossRefGoogle Scholar
  12. 12.
    Moreland L, Schiff M, Baumgartner S, et al.: Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999, 130:478–486. Phase III study of etanercept in treatment of RA.PubMedGoogle Scholar
  13. 13.
    Bathon J, Martin R, Fleischmann R, et al.: A comparison of etanercept and methotrexate in patients with early rheuma-toid arthritis. N Engl J Med 2000, 343:1586–1593. Comparison of etanercept with MTX in the treatment of early RA.PubMedCrossRefGoogle Scholar
  14. 14.
    Genovese M, Bathon J, Martin R, et al.: Etanercept versus meth-otrexate in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:1443–1450.PubMedCrossRefGoogle Scholar
  15. 15.
    Weinblatt M, Kremer J, Bankhurst A, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion pro-tein, in patients with rheumatoid arthritis receiving methotr-exate. N Engl J Med 1999, 340:253–259. Study of etanercept in combination with MTX in RA.PubMedCrossRefGoogle Scholar
  16. 16.
    Maini R, St. Clair E, Breedveld F, et al.: Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomi-tant methotrexate: a randomized phase III trial. Lancet 1999, 354:1932–1939. Phase III study of infliximab in combination with MTX in treat-ment of RA.PubMedCrossRefGoogle Scholar
  17. 17.
    Lipsky P, van der Heijde D, St. Clair E, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343:1594–1602.PubMedCrossRefGoogle Scholar
  18. 18.
    Hansen K, Cush J, Patel S, et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthri-tis [abstract]. Arthritis Rheum 2002, 46(suppl):S538.CrossRefGoogle Scholar
  19. 19.
    Moreland L, Koopman W: Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med 1998, 128:231–233.PubMedGoogle Scholar
  20. 20.
    Amgen Incorporated: Anakinra packaging information. http:/ / Accessed March 20, 2003.Google Scholar
  21. 21.
    Maini R, Breedveld F, Kalden J, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly meth-otrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552–1563.PubMedCrossRefGoogle Scholar
  22. 22.
    Baert F, Noman M, Vermeire S, et al.: Influence of immunoge-nicity on the long-term efficacy of infliximab in Crohn’s dis-ease. N Engl J Med 2003, 348:601–608. Report highlighting the potential role of drug antigenicity in decreased response duration.PubMedCrossRefGoogle Scholar
  23. 23.
    US Food and Drug Administration: Clinical review: Abbott bio-logic licensing application STN 125057 adalimumab for use in the treatment of rheumatoid arthritis. Available at http:// HUMIRA.Med.Review.pdf. Accessed March 20, 2003.Google Scholar
  24. 24.
    Schaible T: Treatment of inflammatory diseases: safety of long-term use of infliximab. Presse Med 2001, 30:610–613.PubMedGoogle Scholar
  25. 25.
    Moreland L, Cohen S, Klareskog L, et al.: Global safety and effi-cacy of more than 5 years of etanercept (ENBREL) therapy in rheumatoid arthritis [abstract]. Arthritis Rheum 2002, 46(suppl):S532.Google Scholar
  26. 26.
    Kindler V, Sappino A, Grau G, et al.: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989, 56:731–740. Highlights the role of TNF in granulomatous infection.PubMedCrossRefGoogle Scholar
  27. 27.
    Mohan V, Scanga C, Yu K, et al.: Effects of tumor necrosis fac-tor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immunol 2001, 69:1847–1855.CrossRefGoogle Scholar
  28. 28.
    Senaldi G, Yin S: Corynebacterium parvum and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF I receptor (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996, 157:5022–5026.PubMedGoogle Scholar
  29. 29.
    Keane J, Gershon S, Wise R, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098–1104. Study highlighting the potential role of TNF inhibition in TB incidence.PubMedCrossRefGoogle Scholar
  30. 30.
    US Food and Drug Administration: Briefing document: update on the TNF alpha blocking agents. Available at http:// Accessed March 20, 2003. An important synopsis of safety issues with the use of TNF antagonists.Google Scholar
  31. 31.
    Bergstrom L, Yocum D, Tesser J, et al.: Coccidiomycosis (Valley Fever) occurring during infliximab therapy [abstract]. Arthri-tis Rheum 2002, 46(suppl):S169.Google Scholar
  32. 32.
    Lee J, Slifman N, Gerhon S, et al.: Life-threatening histoplas-mosis complicating immunotherapy with tumor necrosis fac-tor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565–2570.PubMedCrossRefGoogle Scholar
  33. 33.
    Slifman N, Gershon S, Lee J, et al.: Listeria monocytogenes infection as a complication of treatment with tumor necro-sis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319–324.PubMedCrossRefGoogle Scholar
  34. 34.
    Wolfe F: Inflammatory activity, but not methotrexate or pred-nisone use predicts non-Hodgkin’s lymphoma with rheuma-toid arthritis: a 25-year study of 1767 RA patients [abstract]. Arthritis Rheum 1998, 41(suppl):S188.CrossRefGoogle Scholar
  35. 35.
    Baecklund E, Ekbom A, Sparen P, et al.: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998, 517:180–181.Google Scholar
  36. 36.
    Mohan N, Edwards E, Cupps T, et al.: Demyelination occurring during anti-tumor necrosis factor-a therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862–2869.PubMedCrossRefGoogle Scholar
  37. 37.
    Mease P, Ritchlin C, Martin R, et al.: Response to pneumococ-cal vaccination in patients treated with etanercept trial [abstract]. Arthritis Rheum 2001, 44(suppl):S91.Google Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Ted R. Mikuls
    • 1
  • Arthur L. Weaver
  1. 1.Section of Rheumatology and ImmunologyUniversity of Nebraska Medical Center and the Omaha Veteran’s Administration Medical CenterOmahaUSA

Personalised recommendations